Intelligent Bio Solutions Secures $10.1 Million in At-the-Market Private Placement

Photo of author
Written By Kris Enyinnaya

Intelligent Bio Solutions Inc. (Nasdaq: INBS), a pioneering medical technology company, has successfully concluded a significant private placement, signaling strong market confidence in its innovative, rapid, non-invasive testing solutions.

This strategic financial maneuver raised approximately $10.1 million in gross proceeds, underscoring the company’s robust positioning for future growth and development in the medical technology landscape.

Strategic Financial Milestone

The private placement entailed the issuance of 2,223,333 shares of common stock (or equivalent pre-funded warrants), coupled with Series H-1 and Series H-2 warrants to purchase up to an aggregate of 4,446,666 shares of common stock, priced at a combined purchase price of $4.55 per share (or pre-funded warrant) and associated warrants.

This pricing strategy, executed at-the-market under Nasdaq rules, reflects a judicious approach to capital raising, tailored to align with current market valuations and investor expectations.

Credits: DepositPhotos

The Series H-1 warrants, exercisable immediately upon issuance, carry an eighteen-month term post the effective registration of the warrant shares by the SEC.

Conversely, the Series H-2 warrants extend a five-year exercise term, subject to reduction to 20 days subsequent to any announcement of FDA 510k clearance for the company’s flagship product, the Intelligent Fingerprinting Drug Screening System.

This nuanced structuring of the warrants provides both immediate and long-term incentives for investors, aligning closely with the company’s developmental milestones and regulatory pathways.

Utilization of Proceeds and Strategic Vision

Harry Simeonidis, President and CEO of INBS, articulated the company’s strategic vision for utilizing the proceeds from this capital infusion.

The funds are earmarked for general corporate purposes, with a significant focus on advancing clinical trials for the Intelligent Fingerprinting Drug Screening System and driving market expansion efforts.

This strategic allocation highlights the company’s commitment to innovation and its ambition to redefine non-invasive testing through its groundbreaking technology.

Ladenburg Thalmann & Co. Inc. served as the exclusive placement agent for the transaction, reinforcing the private placement’s credibility and the strategic advisory role played by seasoned financial institutions in facilitating growth in the medical technology sector.

About Intelligent Bio Solutions Inc.

Intelligent Bio Solutions Inc. stands at the forefront of medical technology innovation, with its Intelligent Fingerprinting Drug Screening System poised to revolutionize portable testing.

This cutting-edge technology leverages fingerprint sweat analysis to provide rapid, non-invasive drug screening, offering a hygienic, cost-effective solution for detecting recent use of common workplace substances.

The system’s ease of use—achieving sample collection in seconds and results in under ten minutes—positions it as a valuable tool for employers across various safety-critical industries.

Moreover, the company’s expansive biosensor platform harbors the potential to address up to 130 different indications, ranging from glucose monitoring to immunological conditions and communicable diseases, underscoring the broad applicability and transformative potential of INBS’s technological portfolio.

Forward-Looking Statements and Future Outlook

The announcement contains forward-looking statements regarding INBS’s use of proceeds, development goals, commercialization efforts, partnership potentials, and regulatory ambitions.

These projections reflect the company’s expectations and are based on current market dynamics, technological advancements, and regulatory landscapes.

However, they are subject to inherent risks and uncertainties that could cause actual outcomes to differ materially from those projected.

Credits: DepositPhotos

As Intelligent Bio Solutions Inc. advances on its strategic path, leveraging the newly secured funds for technological advancements and market penetration, the company remains steadfast in its commitment to delivering innovative solutions that address critical needs in the medical and diagnostic testing markets.

This recent financial milestone not only fortifies INBS’s fiscal standing but also reaffirms its strategic direction and potential to impact the medical technology domain profoundly.


You should read and understand this disclaimer in its entirety before joining or viewing the website or email/blog list of (the “Publisher”). The information (collectively the “Advertisement”) disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, and/or losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply. To unsubscribe from receiving promotional text messages to your phone sent via an autodialer, using your phone reply to the sender’s phone number with the word STOP or HELP for help.

The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at; the Financial Industry Regulatory Authority (the "FINRA") at, and relevant State Securities Administrator website and the OTC Markets website at The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete.

The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial and/or legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete.

By your subscription to our profiles, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link: and

By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of (1) a client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink.